Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets

Area of Science:

• Genomics
• Cancer Biology
• Biotechnology

Background:

• Genomic studies highlight breast cancer's complexity and the need for personalized therapies.
• Translating genomic discoveries to clinical practice is hindered by a lack of translatable functional genomic assays.
• Anchorage-independent 3D growth assays are crucial for chemosensitivity testing with high clinical success rates.

Purpose of the Study:

• To evaluate the Cancer BioChip System (CBCS) for simultaneous, quantitative, and real-time assessment of breast cancer cell growth inhibitors.
• To identify 3D-specific effectors of breast cancer cell growth using a Test Cancer BioChip with silencing RNAs (siRNAs).
• To compare the effects of siRNAs on hormone receptor-positive (MCF7) and HER2-positive (SK-BR-3) breast cancer cells in a 3D setting.

Main Methods:

• Utilized a Test Cancer BioChip arrayed with siRNAs targeting cancer-related genes.
• Assessed anchorage-independent colony growth of MCF7 and SK-BR-3 cells in response to specific siRNAs.
• Quantitatively evaluated real-time cell growth inhibition in a 3D culture environment.

Main Results:

• Confirmed cell-specific inhibition of MCF7 by estrogen receptor α (ESR1) siRNA and SK-BR-3 by Human Epidermal Growth Factor Receptor 2 (HER2) siRNA.
• Observed that Phosphoinositide-3-kinase Catalytic, alpha Polypeptide (PIK3CA) siRNA suppressed growth in both cell lines.
• Identified unique 3D-specific responses, with ß-actin (ACTB) siRNA suppressing both cell types and Cathepsin L2 (CTSL2) siRNA showing opposite effects.

Conclusions:

• The CBCS is a valuable tool for identifying clinically relevant breast cancer targets.
• The study highlights the importance of 3D functional assays for discovering context-specific therapeutic targets.
• Results underscore the potential for developing individualized diagnostic and therapeutic strategies based on 3D cell growth dynamics.